Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr:201:113603.
doi: 10.1016/j.ejca.2024.113603. Epub 2024 Feb 5.

Effectiveness and safety of COVID-19 vaccination in people with blood cancer

Emma Copland  1 , Jennifer Hirst  1 , Emma Mi  1 , Martina Patone  1 , Daniel Chen  1 , Carol Coupland  2 , Julia Hippisley-Cox  3
Affiliations
Free article

Effectiveness and safety of COVID-19 vaccination in people with blood cancer

Emma Copland et al. Eur J Cancer. 2024 Apr.
Free article

Abstract

Background: People with blood cancer have increased risk of severe COVID-19 outcomes and poor response to vaccination. We assessed the safety and effectiveness of COVID-19 vaccines in this vulnerable group compared to the general population.

Methods: Individuals aged ≥12 years as of 1st December 2020 in the QResearch primary care database were included. We assessed adjusted COVID-19 vaccine effectiveness (aVE) against COVID-19-related hospitalisation and death in people with blood cancer using a nested matched case-control study. Using the self-controlled case series methodology, we compared the risk of 56 pre-specified adverse events within 1-28 days of a first, second or third COVID-19 vaccine dose in people with and without blood cancer.

Findings: The cohort comprised 12,274,948 individuals, of whom 81,793 had blood cancer. COVID-19 vaccines were protective against COVID-19-related hospitalisation and death in people with blood cancer, although they were less effective, particularly against COVID-19-related hospitalisation, compared to the general population. In the blood cancer population, aVE against COVID-19-related hospitalisation was 64% (95% confidence interval [CI] 48%-75%) 14-41 days after a third dose, compared to 80% (95% CI 78%-81%) in the general population. Against COVID-19-related mortality, aVE was >80% in people with blood cancer 14-41 days after a second or third dose. We found no significant difference in risk of adverse events 1-28 days after any vaccine dose between people with and without blood cancer.

Interpretation: Our study provides robust evidence which supports the use of COVID-19 vaccinations for people with blood cancer.

Keywords: Blood cancer; COVID-19; SARS-CoV-2; Vaccine effectiveness; Vaccine safety.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest This study is funded by Blood Cancer UK. JHC reports grants from National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund, Cancer Research UK and Oxford Wellcome Institutional Strategic Support Fund and other research councils, during the conduct of the study outside the scope of this work. JHC is founder and was shareholder until 9 Aug 2023 of ClinRisk Ltd, which produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. JHC is an unpaid director of QResearch, a not-for-profit organisation which is a partnership between the University of Oxford and EMIS Health who supply the QResearch database used for this work. JHC is an NIHR Senior Investigator outside the scope of this work. CC reports grants from NIHR and research councils outside the scope of this work during the past 36 months. All other authors declare no competing interests.

Substances

LinkOut - more resources